Business Context and Reporting Period
This Form 8-K, filed on February 14, 2024, reports events occurring on February 9, 2024, and February 13, 2024, for Renovaro Inc. (formerly Renovaro Biosciences Inc., ticker: RENB). The filing details the consummation of the acquisition of GEDi Cube Intl Ltd. and related corporate governance changes.
Key Financial Metrics and Transaction Details
- Transaction Consideration: The Company issued 70,834,183 shares of Common Stock as Closing Consideration to GEDi Cube sellers. This includes 67,224,089 shares issued at closing plus 5,610,100 shares resulting from the automatic conversion of Series A Convertible Preferred Stock.
- Ownership Structure: Following the transaction and preferred stock conversion, the Sellers hold approximately 49% of the issued and outstanding Common Stock.
- Share Count: Total Common Stock issued and outstanding increased to 143,668,372 shares.
- Financial Statements: The filing incorporates by reference audited financial statements for GEDi Cube's predecessor (Grace Systems B.V.) for 2021 and 2022. Unaudited pro forma financial statements for the three months ended September 30, 2023, and the year ended June 30, 2023, are attached as Exhibit 99.2.
- Cash Flow and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels for the combined entity or the acquired subsidiary within this specific report.
Material Changes Versus Prior Period
- Corporate Name: The Company changed its name from "Renovaro Biosciences Inc." to "Renovaro Inc." effective February 13, 2024.
- Board Composition: The Board of Directors was expanded from nine to ten members. The number of directors designated by the Company increased from four to five, and the number of required independent directors increased from three to four.
- Director Changes: Henrik Grønfeldt-Sørensen resigned as a director effective at closing. Karen Brink, Chief Growth Officer of GEDi Cube, was appointed to the Board to fill the vacancy.
- Capital Structure: All Series A Convertible Preferred Stock was automatically converted into Common Stock, leaving no Preferred Stock outstanding.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the transaction was approved by stockholders on January 25, 2024. The resignation of Mr. Grønfeldt-Sørensen was stated to be unrelated to any disagreement regarding operations or policies.
- Registration Rights: The Company entered into a Registration Rights Agreement granting sellers customary demand and piggyback rights and agreeing to assist with Rule 144 transfers.
- Future Filings: The Company intends to file an amendment to this 8-K to include audited financial statements for GEDi Cube for the year ended December 31, 2023, and unaudited pro forma statements for the six months ended December 31, 2023, once available.
- Risks: The filing notes that the issuance of shares was unregistered, relying on private offering exemptions (Section 4(a)(2), Rule 506, Regulation S).
Key Facts for Investor Verification
- Verify the pro forma financial impact of the acquisition in Exhibit 99.2, as specific revenue or profit metrics are not detailed in the narrative text.
- Confirm the dilution impact, noting that sellers now control approximately 49% of the outstanding shares.
- Review the Second Amendment to the Stock Purchase Agreement (Exhibit 2.1) for specific governance terms regarding the new board composition.
- Monitor future filings for the audited 2023 financial statements of GEDi Cube, which are not yet included in this report.
- Check the status of the 1 million shares previously issued to a consultant and 1 million shares to director Avram Miller, which were excluded from the Closing Consideration calculation.